Cardiology
DAPT Score
Determines whether to continue dual antiplatelet therapy (DAPT) beyond 12 months after PCI with drug-eluting stent.
Score interpretation
Low Risk — Shorten DAPT -2–1
DAPT Score < 2: Benefit of extended DAPT is outweighed by bleeding risk. Stopping DAPT at 12 months is preferred.
→ Discontinue DAPT (thienopyridine) at 12 months. Continue aspirin alone.
High Risk — Extend DAPT 2–10
DAPT Score ≥ 2: Ischaemic benefit of continued DAPT outweighs bleeding risk.
→ Continue DAPT (aspirin + thienopyridine) beyond 12 months. Reassess periodically.
Interpretation bands for the DAPT. Apply clinical judgement and local guidance.
References
- Yeh RW et al. Population-Level Estimates of Benefit and Harm Imbalances With Dual Antiplatelet Therapy After Coronary Artery Stenting. JAMA Intern Med. 2016;176(8):1140-1149.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Mehran Score for Post-PCI Contrast Nephropathy · Coronary Artery Disease
- Canadian Cardiovascular Society (CCS) Angina Grading · Coronary Artery Disease
- Duke Treadmill Score · Coronary Artery Disease
- ARC-HBR Criteria for High Bleeding Risk in PCI · Coronary Artery Disease
- PRECISE-DAPT Score for Bleeding on DAPT · Coronary Artery Disease
- SYNTAX Score for Coronary Artery Disease · Coronary Artery Disease
Drugs
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.